Nationwide Recall Affects Over 25,000 Bottles
Inventia Healthcare Limited has issued two separate recalls totaling more than 25,000 bottles of 25-milligram chlorthalidone tablets following regulatory testing failures, according to Yahoo News. The action involves batches distributed across the United States that failed to meet established dissolution specifications, raising concerns about how the medication releases its active ingredient in the body.
The affected products include 100-tablet and 1,000-tablet bottles carrying an expiration date of April 2027. Regulatory documentation indicates the specific batch codes involved in the nationwide action are RISA24001, RISB24002, and RISA24002. The Food and Drug Administration assigned official recall numbers D-0610-2026 and D-0852-2026 to the two separate enforcement actions.
Staggered Recalls and Regulatory Classification
The manufacturing defect came to light through phased regulatory enforcement actions. Inventia Healthcare initiated the first recall phase on June 5, pulling 11,460 bottles from distribution channels, as reported by Country Rebel. A secondary recall followed on September 3, removing an additional 13,567 bottles of the blood pressure medication.
The Food and Drug Administration subsequently classified both actions under the Class II category. This designation is applied to products whose use might cause temporary or medically reversible adverse health consequences, with only a remote probability of serious injury. According to USA Today, no illnesses or injuries linked to the recalled lots had been officially reported at the time the classification was issued.
Understanding Dissolution Failures in Diuretics
Chlorthalidone is a prescription thiazide diuretic utilized primarily to manage hypertension and fluid retention. The medication functions by stimulating the kidneys to eliminate excess sodium and water through urination, thereby reducing hemodynamic pressure on blood vessel walls.
Dissolution testing measures the precise rate at which a solid oral dosage form disintegrates and releases its active pharmaceutical ingredient into solution. When a batch experiences a dissolution failure, it indicates the tablets may disintegrate too slowly to ensure the standard systemic absorption of the active compound, potentially diminishing the therapeutic efficacy required for blood pressure control.
Supply Chain and Patient Guidance
While Inventia Healthcare Limited is headquartered in Mumbai, India, the recalled inventory was distributed domestically by Rising Pharma Holdings Inc., which is based in East Brunswick, New Jersey. Regulatory authorities emphasize that patients in possession of the affected medication should consult their health care provider before altering their treatment routines.
Public health guidelines advise that individuals prescribed medications subject to Class II and III recalls should not discontinue usage independently, as abrupt cessation can pose severe cardiovascular risks that outweigh the potential impact of a sub-potent batch. Pharmacists and physicians remain available to verify specific bottle numbers and recommend appropriate clinical alternatives.